Singapore-based healthtech firm Respiree has announced the successful close of a $11.6 million Series A funding round to accelerate its AI-powered patient monitoring platform.
The round was co-led by ClavystBio and We Venture Capital, with participation from Adaptive Capital Partners, Greenwillow Capital Management, Seeds Capital, she1K, and the Mayo Clinic’s Mayo Foundation for Medical Research.
The investment marks a significant milestone in Respiree’s journey to reshape how patients are monitored and cared for using artificial intelligence. The company plans to utilize the funding to expand its commercial footprint in the United States, particularly through its base at the Texas Medical Center Innovation Hub in Houston. This expansion will focus on enhancing business relationships and streamlining operations with existing and new partners across key healthcare markets.
Driving Innovation in Patient Monitoring
Respiree’s AI-powered platform automates patient monitoring and care pathway management, offering healthcare providers real-time insights that can improve patient outcomes.
A core innovation is its predictive AI model, developed through the Mayo Clinic Platform_Accelerate program, which is designed to detect early signs of patient deterioration and minimize false alarms, two critical challenges in hospital and clinical settings.
Expanding Global Healthtech Reach
With active operations in the US, Australia, and across the Asia-Pacific, Respiree is positioning itself as a global leader in AI-powered healthtech. The firm has also announced strategic plans to enter the Gulf Cooperation Council (GCC) and Thailand, signaling a commitment to expanding into emerging digital health markets.
Additionally, Respiree has partnered with Roche Diagnostics to launch pilot programs across Asia-Pacific, showcasing its ability to forge strong collaborations with major healthcare players.
Respiree has secured funding for its AI healthtech solutions, marking a significant step towards global scaling and strengthening collaborations within the healthcare ecosystem.
The backing by global investors and health institutions like the Mayo Clinic not only validates Respiree’s technology but also reinforces the growing demand for intelligent patient monitoring systems in both hospital and homecare environments.
As AI continues to transform the healthcare sector, Respiree’s advancements in automation and predictive analytics position it to lead the next wave of innovation in patient care.
